{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:44:18Z","timestamp":1787071458066,"version":"build-2736575974"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"\n Introduction:<\/jats:title>\n The goal of this study was to find out how SGLT2 inhibitors and GLP-1 receptor agonists help persons with Type 2 Diabetes Mellitus (T2DM) keep their blood sugar levels stable.<\/jats:p>\n <\/jats:sec>\n \n Methodology:<\/jats:title>\n There were 120 people in the trial. They were randomly given either empagliflozin, Canagliflozin, Dapagliflozin, Ertugliflozin, Bexagliflozin, Sotagliflozin (an SGLT2 inhibitor) or liraglutide, Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin (n GLP-1 receptor agonist) to consume for 24 weeks. The major goal was to lower the levels of HbA1c. Some of the secondary outcomes included losing weight, markers of heart health, and adverse events.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n Both treatments brought down HbA1c levels a lot, although GLP-1 agonists brought them down a little bit more. Both groups\u2019 systolic blood pressure and LDL cholesterol levels improved, but the group that took GLP-1 agonists lost more weight. People who took SGLT2 inhibitors didn\u2019t have as many stomach problems, whereas people who took GLP-1 agonists got nauseated and threw up.<\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n The study showed that both types of medicines do a decent job of keeping blood sugar levels steady. But GLP-1 agonists are better at helping people lose weight and keep their hearts healthy, so they are also a fantastic choice for people who have these problems. It\u2019s crucial to consider what each patient needs and what could go wrong while establishing treatment plans for them.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/jpbs.jpbs_1334_25","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T08:00:27Z","timestamp":1766044827000},"page":"S3244-S3246","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Effect of SGLT2 Inhibitors and GLP-1 Agonists on Glycemic Control in Type 2 Diabetes Mellitus"],"prefix":"10.4103","volume":"17","author":[{"given":"Ved","family":"Prakash","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Physiology, All India Institute of Medical Sciences, Gorakhpur, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumya","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Rama Medical College-Hospital and Research Centre, Kanpur, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Rawat","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Himalayan Institute of Medical Science, Dehradun, Uttarakhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit Vasant","family":"Deshpande","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Datta Meghe Medical College, Nagpur, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrit","family":"Podder","sequence":"additional","affiliation":[{"name":"Department of Physiology, Teerthanker Mahaveer Medical College and Research Centre, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parth","family":"Jani","sequence":"additional","affiliation":[{"name":"Department of General Medicine, All India Institute of Medical Sciences, Rajkot, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"R1-20251218","doi-asserted-by":"crossref","first-page":"48","DOI":"10.63150\/osjdhs.2025.1","article-title":"Diabetes and dental woes: A study on burden of oral diseases in type 2 diabetes mellitus patients in Mysuru","volume":"1","author":"Premalatha","year":"2025","journal-title":"Oral Sphere J Dent Health Sci"},{"key":"R3-20251218","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.6026\/9732063002001862","article-title":"Clinical study evaluating antihyperglycemic efficacy and safety of Terminalia arjuna versus sitagliptin in Type-2 diabetes mellitus patients","volume":"20","author":"Prakash","year":"2024","journal-title":"Bioinformation"},{"key":"R4-20251218","doi-asserted-by":"crossref","first-page":"26","DOI":"10.18231\/j.ijpp.2020.006","article-title":"Comparative study analyzing efficacy and safety of sitagliptin with metformin versus glimepiride with metformin on patients of type-2 diabetes mellitus","volume":"7","author":"Prakash","year":"2020","journal-title":"Indian J Pharm Pharmacol"},{"key":"R5-20251218","doi-asserted-by":"crossref","first-page":"127","DOI":"10.18231\/j.ijpca.2019.023","article-title":"Study comparing the hypolipidemic effects of Terminalia arjuna with Rosuvastatin on triglyceride and high-density lipoprotein-cholesterol levels","volume":"6","author":"Prakash","year":"2019","journal-title":"Int J Pharm Chem Anal"},{"key":"R7-20251218","first-page":"322","article-title":"SGLT2 inhibitors vs. GLP-1 agonists to treat the heart, the kidneys and the brain","volume":"10","author":"Rolek","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"key":"R8-20251218","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.7150\/ijbs.59965","article-title":"GLP-1 receptor agonists (GLP-1RAs): Cardiovascular actions and therapeutic potential","volume":"17","author":"Ma","year":"2021","journal-title":"Int J Biol Sci"},{"key":"R9-20251218","doi-asserted-by":"crossref","first-page":"100477","DOI":"10.1016\/j.ajpc.2023.100477","article-title":"Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists","volume":"13","author":"Khedagi","year":"2023","journal-title":"Am J Prev Cardiol"}],"container-title":["Journal of Pharmacy and Bioallied Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jpbs.jpbs_1334_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:46:26Z","timestamp":1787067986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jpbs.jpbs_1334_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":7,"journal-issue":{"issue":"Suppl 4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jpbs.jpbs_1334_25","relation":{},"ISSN":["0976-4879","0975-7406"],"issn-type":[{"value":"0976-4879","type":"print"},{"value":"0975-7406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"2025-08-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}